Pfizer's Remicade Biosimilar: Sept. 15 Is Earliest Launch Date
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Celltrion agreed not to market Inflectra, their biosimilar to Janssen's blockbuster TNF-inhibitor, before mid-September barring certain circumstances.
You may also be interested in...
Pfizer Eliminates Roadblock To Remicade Biosimilar Launch
October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.
Pfizer Eliminates Roadblock To Remicade Biosimilar Launch
October launch seems more certain after district court rules patent covering the antibody is invalid; litigation continues over cell culture media patent that expires in 2027.
Evolving Biosimilar Pathway Brings Mid-Review Policy Issues
Drug Review Profile: Labeling, unique fee structure among many challenges that Inflectra sponsor Celltrion and FDA had to navigate in nascent regulatory pathway.